Better Health. Better Life.

Life Sciences and Biotechnology Leader Douglas Janzen Named Senior Clinical Advisor of M Pharmaceutical, Inc.

Internationally-Recognized Life Sciences Executive Joins the Advisory Board of Canadian Company Specializing in Biomedical Technologies for Obesity & Diabetes

 

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 19, 2015) - M Pharmaceutical Inc. ("M Pharmaceutical" or the "Company") (CSE:MQ), is pleased to announced that Douglas Janzen of Vancouver - an established leader in the life sciences and biotechnology sectors with more than 20 years of leadership experience in corporate finance, business development and management - has been appointed Senior Clinical Advisor of the Company.

Janzen, the Co-Founder and Managing Director of Northview Ventures, and President and CEO of Aequus Pharmaceuticals, will immediately join the Advisory Board of M Pharmaceutical, a Canadian company committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes.

"We are of course very pleased to have someone of Douglas's stature and background join us as Senior Clinical Advisor," said Dr. Martin Mintchev, President and Chief Executive Officer of M Pharmaceutical. "With his leadership reputation in biotechnology, pharma and life sciences and an impressive toolkit in the areas of entrepreneurship, finance and business development, Douglas is bound to deliver significant added value to everything we do in bringing our own innovative biomedical technologies to market."

Recognized for his passion for life sciences and biotechnology, Janzen serves on the boards of Neovasc, Aequus, Alabaster Technologies, Ico Therapeutics, Perimeter Medical Imaging, Renaissance Biosciences and Synaptive Technologies.

Before founding Northview Ventures, a strategic investment and consulting firm focused on life sciences and high tech, he served nine years as a senior executive at Cardiome Pharma, where he held the leadership positions of Chief Financial Officer (2003 - 2005), President and Chief Business Officer (2005 - 2009), and President and Chief Executive Officer (2009 - 2012).

At Cardiome, Janzen raised over $300 million from investors and completed over $1 billion in licensing deals. He formed the partnership with Merck that brought Cardiome's flagship product "Brinavess" through to clinical approval and marketing in Europe.

Prior to Cardiome, Janzen was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. He has completed over $1 billion in equity financing for Canadian bio-tech companies and has previously served as chair of LifeSciences BC and as a director with Biotech Canada. Janzen is also a former winner of Business in Vancouver's "Top 40 Under 40 Award".

About M Pharmaceutical Inc.

M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes. The Company currently has the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose in diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. Commercial development of the eMosquito, the pseudobezoar and the neurostimulator technologies will require successful coordination and execution of a wide variety of technology disciplines.

FORWARD LOOKING STATEMENTS

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the effect of the appointment of Mr. Janzen will have on the Company. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to complete the commercialization of the eMosquito, the temporary pseudobezoars and the neurostimulator technologies.

 

FOR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
604.428.0511
info@m-pharma.ca
www.m-pharma.ca

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.